Contribution of ADA1A polymorphism to persistent pain states

ADA1A 多态性对持续性疼痛状态的影响

基本信息

  • 批准号:
    7864158
  • 负责人:
  • 金额:
    $ 4.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-07-01 至 2011-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Millions of Americans suffer from unrelieved persistent pain, which has a devastating effect on their quality of life and severely burdens our health care system. There is growing evidence that intractable pain is frequently comorbid with anxiety, depression, and other psychological traits, often manifesting as hypersensitivity disorders in which the underlying physical substrate of the pain is unknown. The role of cognitive and affective risk factors in the development of these idiopathic pain conditions has not been adequately explored. A compelling explanation for the development of idiopathic disorders, such as fibromyalgia, irritable bowel syndrome, and temporomandibular joint disease (TMD), is disregulation of the adrenergic neurotransmitter system. Polymorphic variants of several genes encoding adrenergic receptors have been shown to elevate risk for developing TMD; these genes have also been associated with negative mood and cognitive effects. This proposal will investigate the relationship between alpha-adrenergic receptor (ADRA) gene polymorphisms and risk factors for chronic pain using genetic techniques and murine models of behavior. Our preliminary studies with a small prospective cohort showed a strong link between genetic variants of ADRA1A and risk of TMD development. Here we would like to employ a novel case control study population to verify and extend these preliminary findings. To confirm the contribution of alpha-adrenergic receptors to pain sensitivity and affective states in vivo, we will use mouse inflammatory pain and behavioral models. To investigate potential molecular mechanisms underlying the observed associations, individual variations in ADRA1A expression patterns will be studied in white blood cell samples collected from each subject enrolled in the study. These experiments will provide a better understanding of how adrenergic neuromodulation contributes to pathological nociceptive and affective states, ultimately leading to the development of a persistent pain condition. Identifying genetic and environmental risk factors for TMD will allow for the development of precise diagnostic tools, and provide novel targets for analgesic therapies. Determining the genetic and environmental risk factors for the development of persistent pain disorders such as TMD is crucial for diagnosing and treating these debilitating diseases. This proposal will explore the causes of TMD in a population of chronic pain patients, and investigate the molecular mechanisms by which adrenergic receptors contribute to pain sensitivity and negative mood traits.
描述(由申请人提供):数以百万计的美国人患有无法缓解的持续性疼痛,这对他们的生活质量产生了毁灭性影响,并给我们的医疗保健系统带来了严重负担。越来越多的证据表明,顽固性疼痛经常与焦虑、抑郁和其他心理特征共存,通常表现为过敏性疾病,其中疼痛的潜在物理基础尚不清楚。认知和情感危险因素在这些特发性疼痛病症发展中的作用尚未得到充分探讨。纤维肌痛、肠易激综合征和颞下颌关节病 (TMD) 等特发性疾病的发生的一个令人信服的解释是肾上腺素能神经递质系统的失调。多个编码肾上腺素受体的基因的多态性变异已被证明会增加患 TMD 的风险;这些基因也与负面情绪和认知影响有关。该提案将利用遗传技术和小鼠行为模型研究α-肾上腺素能受体(ADRA)基因多态性与慢性疼痛危险因素之间的关系。我们对一个小型前瞻性队列进行的初步研究表明,ADRA1A 的遗传变异与 TMD 发展风险之间存在密切联系。在这里,我们想采用一种新颖的病例对照研究人群来验证和扩展这些初步发现。为了确认α-肾上腺素能受体对体内疼痛敏感性和情感状态的贡献,我们将使用小鼠炎症疼痛和行为模型。为了研究观察到的关联背后的潜在分子机制,将从参与研究的每个受试者收集的白细胞样本中研究 ADRA1A 表达模式的个体差异。这些实验将更好地理解肾上腺素能神经调节如何促进病理性伤害感受和情感状态,最终导致持续性疼痛状况的发展。识别 TMD 的遗传和环境风险因素将有助于开发精确的诊断工具,并为镇痛治疗提供新的靶标。确定 TMD 等持续性疼痛疾病发生的遗传和环境风险因素对于诊断和治疗这些使人衰弱的疾病至关重要。该提案将探讨慢性疼痛患者群体 TMD 的原因,并研究肾上腺素能受体导致疼痛敏感性和负面情绪特征的分子机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shad Benjamin Smith其他文献

Shad Benjamin Smith的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shad Benjamin Smith', 18)}}的其他基金

Single-cell omics approaches to investigate TMD
研究 TMD 的单细胞组学方法
  • 批准号:
    10524285
  • 财政年份:
    2022
  • 资助金额:
    $ 4.96万
  • 项目类别:
Contribution of ADA1A polymorphism to persistent pain states
ADA1A 多态性对持续性疼痛状态的影响
  • 批准号:
    7485979
  • 财政年份:
    2008
  • 资助金额:
    $ 4.96万
  • 项目类别:
Contribution of ADA1A polymorphism to persistent pain states
ADA1A 多态性对持续性疼痛状态的影响
  • 批准号:
    7652474
  • 财政年份:
    2008
  • 资助金额:
    $ 4.96万
  • 项目类别:

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 4.96万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 4.96万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 4.96万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 4.96万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 4.96万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 4.96万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 4.96万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 4.96万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 4.96万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 4.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了